■ Launched a new product in 5 years since 2017 HelloGene 3.0 version, obtaining 141 testing types in Korea

■ Upgrade testing types of existing cancer and chronic disease and add types of new mental health … Approved by Korea Centers for Disease Control and Prevention

 

[2022.04.13] Theragen Bio (CEO: Hwang Tae-soon), a global genome service provider and AI-based biopharmaceutical company, has launched "Hello Gene 4.0," a disease prediction personal genetic test service. This upgrade is the first change in five years since the "Hello Gene 3.0" version, which was released in 2017 by supplementing Korean genes and markers.

 

In the case of the disease prediction personal genetic test service "Hello Gene 4.0", it is a disease prediction genetic test that can be requested to a medical institution to conduct a blood collection service and receive genetic test results from medical experts at the requested institution. It has a genetic analysis algorithm based on a Korean database and is repeatedly reported by research groups of various races, and is characterized by selecting meaningful genes. In addition, three or more multi-markers were used for each disease to increase the accuracy of disease prediction.

 

In "Hello Gene 4.0," the number of markers and genes verified in Koreans and Asians has nearly doubled, and the number of test typeshas also increased from 97 to 141, an increase of about 69% compared to the previous version. 12 cancers and 33 general diseases, which have been reported more actively than the previous 3.0 version, were added, and customized test types for mental health that fit in the recent healthcare trend were also added for the first time in Korea. The design of the test result also improved user convenience with icons and easy explanations.

 

Theragen Bio has the largest number of test types in the industry with 141 types in cancer, general diseases, drug responses, and rare diseases based on disease predictability among domestic genetic testing companies. Based on the world's first genetic analysis of Koreans, it is the only company in Asia with 12 years of service experiences. So far, personal genetic testing has been provided through more than 700 medical institutions in Korea.

 

Meanwhile, HelloGene, a disease prediction personal genetic test service, was upgraded to 2.0 version in 2013 in cooperation with 15 university hospitals in Korea, released 3.0 version in 2017, and has 12 years of service experiences after launch of HelloGene 1.0 version first in Asia in February 2010.

 

▶ Introduction of Theragen Bio

Theragen Bio provides genome service to more than 700 domestic medical and research institutes over 40 countries abroad, being as a global genome service provider and AI-based biopharmaceutical company specializing in the development of the fourth-generation personalized anti-cancer drugs. Theragenbio strives to realize precision medicine based on genomic technology, thereby providing the true hope and practical solutions for welfare and health of mankind.